Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F13%3A%230000146" target="_blank" >RIV/26475821:_____/13:#0000146 - isvavai.cz</a>

Result on the web

<a href="http://ar.iiarjournals.org/content/33/4/1705.long" target="_blank" >http://ar.iiarjournals.org/content/33/4/1705.long</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.

Original language description

BACKGROUND: Epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene (KRAS) and phosphatidylinositide-3-kinase catalytic subunit-alpha (PIK3CA) mutations are biomarkers used for the prediction of efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: In total, 223 patients with advanced-stage squamous cell NSCLC were tested; 179 patients were treated with EGFR-TKIs. Genetic testing was performed using a combinationof denaturing capillary electrophoresis and direct Sanger sequencing. RESULTS: EGFR mutations were detected in 7.2%; KRAS mutations in 7.4% and PIK3CA mutations in 3.8% of patients. No correlation of EGFR or PIK3CA mutation status with progression-freesurvival (PFS) (p=0.425; p=0.197), nor overall survival (OS) (p=0.673; p=0.687), was observed. KRAS mutations correlated with shorter OS (p=0.039), but not with PFS (p=0.120). CONCLUSION: We did not observe any role of EGFR, KRAS, PIK3CA

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

<a href="/en/project/NR9087" target="_blank" >NR9087: Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anticancer Research

ISSN

1791-7530

e-ISSN

—

Volume of the periodical

33

Issue of the periodical within the volume

4

Country of publishing house

GR - GREECE

Number of pages

7

Pages from-to

1705-1711

UT code for WoS article

—

EID of the result in the Scopus database

—